Abstract
NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) catalyzes the oxidation of 15(S)-hydroxyl group of prostaglandins and lipoxins resulting in the formation of 15-keto metabolites which exhibit greatly reduced biological activities. Therefore, this enzyme has been considered the key enzyme responsible for the inactivation of prostaglandins and lipoxins. Both the cDNA and the genomic DNA of the 15-PGDH gene have been cloned. Structural characterization, transcriptional regulation and biological functions of this enzyme have been investigated. Molecular modeling corroborated with site-directed mutagenesis has identified key residues and domains involved in coenzyme and substrate binding. Catalytic mechanism has been proposed. Studies on the regulation of enzyme expression and activity by physiological and pharmacological agents have begun to uncover its significant roles in cancer, inflammation and reproduction. Apparently, 15-PGDH works with cyclooxygenase-2 to control the cellular levels of prostaglandins. Their reciprocal regulation within the same cells appears to determine the fate of the cells. Because of its ability to inactivate both prostaglandins and lipoxins of two opposite biological activities, the roles of 15-PGDH in cancer and inflammation are particularly intriguing and challenging. Future investigations in these areas are warranted.
Keywords: Dehydrogenase, Lipoxins, Prostaglandins, Enzyme Structure, Reproduction, Inflammation, Cancer
Current Pharmaceutical Design
Title: NAD+-Linked 15-Hydroxyprostaglandin Dehydrogenase: Structure and Biological Functions
Volume: 12 Issue: 8
Author(s): H- H. Tai, H. Cho, M. Tong and Y. Ding
Affiliation:
Keywords: Dehydrogenase, Lipoxins, Prostaglandins, Enzyme Structure, Reproduction, Inflammation, Cancer
Abstract: NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) catalyzes the oxidation of 15(S)-hydroxyl group of prostaglandins and lipoxins resulting in the formation of 15-keto metabolites which exhibit greatly reduced biological activities. Therefore, this enzyme has been considered the key enzyme responsible for the inactivation of prostaglandins and lipoxins. Both the cDNA and the genomic DNA of the 15-PGDH gene have been cloned. Structural characterization, transcriptional regulation and biological functions of this enzyme have been investigated. Molecular modeling corroborated with site-directed mutagenesis has identified key residues and domains involved in coenzyme and substrate binding. Catalytic mechanism has been proposed. Studies on the regulation of enzyme expression and activity by physiological and pharmacological agents have begun to uncover its significant roles in cancer, inflammation and reproduction. Apparently, 15-PGDH works with cyclooxygenase-2 to control the cellular levels of prostaglandins. Their reciprocal regulation within the same cells appears to determine the fate of the cells. Because of its ability to inactivate both prostaglandins and lipoxins of two opposite biological activities, the roles of 15-PGDH in cancer and inflammation are particularly intriguing and challenging. Future investigations in these areas are warranted.
Export Options
About this article
Cite this article as:
Tai H. H-, Cho H., Tong M. and Ding Y., NAD+-Linked 15-Hydroxyprostaglandin Dehydrogenase: Structure and Biological Functions, Current Pharmaceutical Design 2006; 12 (8) . https://dx.doi.org/10.2174/138161206776055958
DOI https://dx.doi.org/10.2174/138161206776055958 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Preface [Hot Topic: Endocrinology Meets Molecular Oncology: Beyond Radioactive Iodine (Guest Editor: Robert C. Smallridge)]
Current Drug Targets - Immune, Endocrine & Metabolic Disorders A Molecular Guidance System Based Upon Target Genes, Nuclear Receptors and Ligands Applied to Drug Discovery and Prediction of Toxicity
Mini-Reviews in Medicinal Chemistry MicroRNAs in Aortic Disease
Current Topics in Medicinal Chemistry Anti-cancer Research on Arnebiae radix-derived Naphthoquinone in Recent Five Years
Recent Patents on Anti-Cancer Drug Discovery New Technologies in Male Contraception
Current Women`s Health Reviews Neuroprotective Mechanisms of Oxygen and Ethanol: A Potential Combination Therapy in Stroke
Current Medicinal Chemistry Biomedical Text Data Mining: Recent Patents
Recent Patents on Computer Science Progress in the Research on Naturally Occurring Flavones and Flavonols: An Overview
Current Organic Chemistry The Cellular Uptake and Apoptotic Efficiency of Colchicine is Correlated with Downregulation of MMP-9 mRNA Expression in SW480 Colon Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Antibodies in Diagnostic Applications
Current Pharmaceutical Biotechnology Minimally Invasive Surgery for Uterine Fibroids with Contained Tissue Extraction
Current Women`s Health Reviews Review: The Role of Radiolabeled DOTA-Conjugated Peptides for Imaging and Treatment of Childhood Neuroblastoma
Current Radiopharmaceuticals Allergenic Tropomyosins and Their Cross-Reactivities
Protein & Peptide Letters Brachytherapy: State of the Art and Possible Improvements
Anti-Cancer Agents in Medicinal Chemistry Breaking the DNA Damage Response via Serine/Threonine Kinase Inhibitors to Improve Cancer Treatment
Current Medicinal Chemistry Cellular Signaling Crosstalk Between Multiple Receptors for Investigation of Pathophysiology in Multifactorial Diseases - What is Clinically-Relevant Crosstalk?
Current Medicinal Chemistry Amino Acid Transporter-Targeted Radiotracers for Molecular Imaging in Oncology
Current Medicinal Chemistry Lung Cancer May Increase Serum Procalcitonin Level
Infectious Disorders - Drug Targets Novel Targeting of Apoptosis Pathways for Prostate Cancer Therapy
Current Cancer Drug Targets Targeting Apoptosis Pathway with Natural Terpenoids: Implications for Treatment of Breast and Prostate Cancer
Current Drug Targets